Background
Methods
Systematic literature review
Outcome evaluation
Statistical analysis
Results
Search results
Study | Restriction | Interventions | N |
---|---|---|---|
Aerts et al. (2013) [49] (NVALT-10) | Nonsquamous histology | Erlotinib (150 mg) | 73 |
Erlotinib (150 mg) + pemetrexed (500 mg/m2) | 82 | ||
Aerts et al. (2013) [49] (NVALT-10) | Squamous histology | Erlotinib (150 mg) | 42 |
Docetaxel (75 mg/m2) + erlotinib (150 mg) | 34 | ||
Auliac et al. (2014) [50] | EGFR mutation negative or unknown | Docetaxel (75 mg/m2) | 74 |
Docetaxel (75 mg/m2) + erlotinib (150 mg) | 73 | ||
Borghaei et al. (2015) [39] (CheckMate 057) | Not restricted | Docetaxel (75 mg/m2) | 224 |
Nivolumab 3 mg/kg | 231 | ||
Brahmer et al. (2015)e [40] (CheckMate 017) | Not restricted | Docetaxel (75 mg/m2) | 108 |
Nivolumab 3 mg/kg | 117 | ||
Camps et al. (2006) [51] | Not restricted | Docetaxel (75 mg/m2) | 129 |
Frequent low-dose docetaxel | 125 | ||
Fossella (2000) [52] | Not restricted | Docetaxel (75 mg/m2) | 125 |
Docetaxel (100 mg/m2) | 125 | ||
Garassino et al. (2013) [53] (TAILOR) | EGFR mutation negative | Docetaxel (75 mg/m2) | 110 |
Erlotinib 150 mg | 109 | ||
Garon et al. (2014) [54] (REVEL) | Not restricted | Docetaxel (75 mg/m2) | 618 |
Docetaxel (75 mg/m2) + ramucirumab (10 mg/kg) | 622 | ||
Gervais et al. (2005) [55] | Not restricted | Docetaxel (75 mg/m2) | 62 |
Frequent low-dose docetaxel | 63 | ||
Gridelli et al. (2004) [56] (DISTAL 01) | Not restricted | Docetaxel (75 mg/m2) | 110 |
Frequent low-dose docetaxel | 110 | ||
Han et al. (2011) [57] | Not restricted | Docetaxel (75 mg/m2) | 40 |
Pemetrexed (500 mg/m2) | 44 | ||
Not restricted | Docetaxel (75 mg/m2) | 288 | |
Pemetrexed (500 mg/m2) | 283 | ||
Hanna et al. (2013) [59] (LUME-Lung 2) | Not restricted | Pemetrexed (500 mg/m2) | 360 |
Pemetrexed (500 mg/m2) + nintedanib (200 mg) | 353 | ||
Hosomi et al. (2015) [60] | Asian population | Docetaxel (60 mg/m2) | 81 |
Docetaxel (60 mg/m2) + ramucirumab (10 mg/kg) | 76 | ||
Juan et al. (2015) [61] | Not restricted | Erlotinib (150 mg) | 35 |
Docetaxel (75 mg/m2) + erlotinib (150 mg) | 33 | ||
Karampeazis et al. (2013) [62] (NCT00440414) | Not restricted | Erlotinib (150 mg) | 39 |
Pemetrexed (500 mg/m2) | 36 | ||
Asian population | Erlotinib (150 mg) | 252 | |
Gefitinib (250 mg) | 250 | ||
Kawaguchi et al. (2014) [46] (DELTA) | Asian population | Erlotinib (150 mg) | 150 |
Docetaxel (60 mg/m2) | 151 | ||
Kim et al. (2008) [64] | Not restricted | Docetaxel (75 mg/m2) | 710 |
Gefitinib (250 mg) | 723 | ||
Kim et al. (2014) [65] | Asian population | Pemetrexed (500 mg/m2) | 45 |
Gefitinib (250 mg) | 43 | ||
Lee et al. (2013) [66] | Not restricted | Erlotinib (150 mg) | 82 |
Pemetrexed (500 mg/m2) | 77 | ||
Erlotinib (150 mg) + pemetrexed (500 mg/m2) | 75 | ||
Nishino et al. (2015) [67] | Nonsquamous histology Asian population | Docetaxel (60 mg/m2) + bevacizumab (15 mg/kg) | 45 |
S-1 (40 mg/m2) + bevacizumab (15 mg/kg) | 45 | ||
Quoix et al. (2004) [68] | Not restricted | Docetaxel (75 mg/m2) | 93 |
Docetaxel (100 mg/m2) | 89 | ||
Reck et al. (2014) [38] (LUME-Lung 1) | Not restricted | Docetaxel (75 mg/m2) | 615 |
Docetaxel (75 mg/m2) + nintedanib (200 mg) | 598 | ||
Schuette et al. (2005) [69] | Not restricted | Docetaxel (75 mg/m2) | 103 |
Frequent low-dose docetaxel | 105 | ||
Shepherd et al. (2000) [70] | Not restricted | Docetaxel (75 mg/m2) | 55 |
Best supportive care | 49 | ||
Sun et al. (2012) [34] (KCSG-LU08–01) | Adenocarcinoma histology Asian population | Pemetrexed (500 mg/m2) | 67 |
Gefitinib (250 mg) | 68 | ||
Sun et al. (2013) [71] (JMID) | Asian population | Docetaxel (75 mg/m2) | 98 |
Pemetrexed (500 mg/m2) | 104 | ||
Nonsquamous histology Progressed after treatment with bevacizumab plus a platinum-based doublet. Asian population | Docetaxel (60 mg/m2) | 50 | |
Docetaxel (60 mg/m2) + bevacizumab (15 mg/kg) | 50 | ||
Nonsquamous histology EGFR mutation negative Asian population | Pemetrexed (500 mg/m2) | 76 | |
Gefitinib (250 mg) | 81 |
Proportional hazards, heterogeneity and inconsistency, and modeling issues
Presentation of results
Histology | PD-L1 expression | EGFR mutation | Occurrence (Non-Asian) | Occurrence (Asian) | OS (Hazard ratio NMA) | PFS (Fractional polynomial NMA) |
---|---|---|---|---|---|---|
Non-squamous | < 5% | Negative | 32.8% | 21.2% | Docetaxel + nintedanib: 2.6 (0.1, 5.6) Docetaxel + ramucirumab: 2.3 (0.3, 4.6) | Docetaxel + ramucirumab: 1.2 (0.6, 1.9) |
Squamous | < 5% | Negative | 21.0% | 20.2% | Nivolumab: 5.5 (0.7, 12.4) Docetaxel + ramucirumab: 2.0 (0.3, 4.0) | Nivolumab: 2.6 (0.0, 5.8)a Docetaxel + ramucirumab: 1.2 (0.6, 1.9) |
Non-squamous | ≥ 5% | Negative | 20.5% | 13.3% |
Nivolumab: 12.9 (5.6, 23.8)
Docetaxel + nintedanib: 2.6 (0.1, 5.6) Docetaxel + ramucirumab: 2.3 (0.3, 4.6) |
Nivolumab: 5.0 (2.2, 8.2)
Docetaxel + ramucirumab: 1.2 (0.6, 1.9) |
Squamous | ≥ 5% | Negative | 13.2% | 12.7% | Nivolumab 8.0 (1.6, 17.8) Docetaxel + ramucirumab: 2.0 (0.3, 4.0) |
Nivolumab: 5.7 (1.8, 10.1)
Docetaxel + ramucirumab: 1.2 (0.6, 1.9) |
Non-squamous | < 5% | Positive | 7.2% | 18.8% |
Docetaxel + erlotinib: 13.4 (4.8, 27.0)
Erlotinib + pemetrexed: 8.0 (0.3, 28.5) Erlotinib: 7.4 (2.5, 14.9) Gefitinib: 4.4 (0.8, 10.5) Docetaxel + nintedanib: 2.6 (0.1, 5.6) Docetaxel + ramucirumab: 2.3 (0.3, 4.6) |
Docetaxel + erlotinib: 8.1 (4.9, 10.9)
Erlotinib + pemetrexed: 7.0 (1.2, 14.6)
Erlotinib: 6.8 (3.4, 11.3)
Gefitinib: 5.4 (2.7, 8.6)
Docetaxel + ramucirumab: 1.2 (0.6, 1.9) |
Squamous | < 5% | Positive | 0.5% | 1.3% |
Docetaxel + erlotinib: 11.9 (4.2, 23.8)
Erlotinib: 6.5 (2.2, 13.2) Nivolumab: 5.5 (0.7, 12.4) Gefitinib: 3.9 (0.7, 9.3) Docetaxel + ramucirumab: 2.0 (0.3, 4.0) |
Docetaxel + erlotinib: 8.1 (4.9, 10.9)
Erlotinib: 6.8 (3.4, 11.3)
Gefitinib: 5.4 (2.7, 8.6)
Nivolumab: 2.6 (0.0, 5.8)a Docetaxel + ramucirumab: 1.2 (0.6, 1.9) |
Non-squamous | ≥ 5% | Positive | 4.5% | 11.8% |
Docetaxel + erlotinib: 13.4 (4.8, 27.0)
Nivolumab: 12.9 (5.6, 23.8)
Erlotinib + pemetrexed: 8.0 (0.3, 28.5) Erlotinib: 7.4 (2.5, 14.9) Gefitinib: 4.4 (0.8, 10.5) Docetaxel + nintedanib: 2.6 (0.1, 5.6) Docetaxel + ramucirumab: 2.3 (0.3, 4.6) |
Docetaxel + erlotinib: 8.1 (4.9, 10.9)
Erlotinib + pemetrexed: 7.0 (1.2, 14.6)
Erlotinib: 6.8 (3.4, 11.3)
Gefitinib: 5.4 (2.7, 8.6)
Nivolumab: 5.0 (2.2, 8.2)
Docetaxel + ramucirumab: 1.2 (0.6, 1.9) |
Squamous | ≥ 5% | Positive | 0.3% | 0.8% |
Docetaxel + erlotinib: 11.9 (4.2, 23.8)
Nivolumab 8.0 (1.6, 17.8) Erlotinib: 6.5 (2.2, 13.2) Gefitinib: 3.9 (0.7, 9.3) Docetaxel + ramucirumab: 2.0 (0.3, 4.0) |
Docetaxel + erlotinib: 8.1 (4.9, 10.9)
Erlotinib: 6.8 (3.4, 11.3)
Nivolumab: 5.7 (1.8, 10.1)
Gefitinib: 5.4 (2.7, 8.6)
Docetaxel + ramucirumab: 1.2 (0.6, 1.9) |